Edward Stenehjem1,2, Adam L Hersh3, Xiaoming Sheng4, Peter Jones1, Whitney R Buckel5, James F Lloyd6, Stephen Howe6, R Scott Evans7,6, Tom Greene4, Andrew T Pavia3. 1. Division of Clinical Epidemiology and Infectious Diseases. 2. Division of Infectious Diseases, Stanford University School of Medicine, California. 3. Division of Pediatric Infectious Diseases. 4. Study Design and Biostatistics Center, University of Utah School of Medicine. 5. Department of Pharmacy, Intermountain Medical Center, Murray. 6. Medical Informatics, Intermountain Healthcare, Salt Lake City, Utah. 7. Biomedical Informatics, University of Utah.
Abstract
BACKGROUND: Antibiotic use and misuse is driving drug resistance. Much of US healthcare takes place in small community hospitals (SCHs); 70% of all US hospitals have <200 beds. Antibiotic use in SCHs is poorly described. We evaluated antibiotic use using data from the National Healthcare and Safety Network antimicrobial use option from the Centers for Disease Control and Prevention. METHODS: We used Intermountain Healthcare's monthly antibiotic use reports for 19 hospitals from 2011 to 2013. Hospital care units were categorized as intensive care, medical/surgical, pediatric, or miscellaneous. Antibiotics were categorized based on spectrum of coverage. Antibiotic use rates, expressed as days of therapy per 1000 patient-days (DOT/1000PD), were calculated for each SCH and compared with rates in large community hospitals (LCHs). Negative-binomial regression was used to relate antibiotic use to predictor variables. RESULTS: Total antibiotic use rates varied widely across the 15 SCHs (median, 436 DOT/1000PD; range, 134-671 DOT/1000PD) and were similar to rates in 4 LCHs (509 DOT/1000PD; 406-597 DOT/1000PD). The proportion of patient-days spent in the respective unit types varied substantially within SCHs and had a large impact on facility-level rates. Broad-spectrum antibiotics accounted for 26% of use in SCHs (range, 8%-36%), similar to the proportion in LCHs (32%; range, 26%-37%). Case mix index, proportion of patient-days in specific unit types, and season were significant predictors of antibiotic use. CONCLUSIONS: There is substantial variation in patterns of antibiotic use among SCHs. Overall usage in SCHs is similar to usage in LCHs. Small hospitals need to become a focus of stewardship efforts.
BACKGROUND: Antibiotic use and misuse is driving drug resistance. Much of US healthcare takes place in small community hospitals (SCHs); 70% of all US hospitals have <200 beds. Antibiotic use in SCHs is poorly described. We evaluated antibiotic use using data from the National Healthcare and Safety Network antimicrobial use option from the Centers for Disease Control and Prevention. METHODS: We used Intermountain Healthcare's monthly antibiotic use reports for 19 hospitals from 2011 to 2013. Hospital care units were categorized as intensive care, medical/surgical, pediatric, or miscellaneous. Antibiotics were categorized based on spectrum of coverage. Antibiotic use rates, expressed as days of therapy per 1000 patient-days (DOT/1000PD), were calculated for each SCH and compared with rates in large community hospitals (LCHs). Negative-binomial regression was used to relate antibiotic use to predictor variables. RESULTS: Total antibiotic use rates varied widely across the 15 SCHs (median, 436 DOT/1000PD; range, 134-671 DOT/1000PD) and were similar to rates in 4 LCHs (509 DOT/1000PD; 406-597 DOT/1000PD). The proportion of patient-days spent in the respective unit types varied substantially within SCHs and had a large impact on facility-level rates. Broad-spectrum antibiotics accounted for 26% of use in SCHs (range, 8%-36%), similar to the proportion in LCHs (32%; range, 26%-37%). Case mix index, proportion of patient-days in specific unit types, and season were significant predictors of antibiotic use. CONCLUSIONS: There is substantial variation in patterns of antibiotic use among SCHs. Overall usage in SCHs is similar to usage in LCHs. Small hospitals need to become a focus of stewardship efforts.
Authors: Deverick J Anderson; Shera Watson; Rebekah W Moehring; Lauren Komarow; Matthew Finnemeyer; Rebekka M Arias; Jacqueline Huvane; Carol Bova Hill; Nancie Deckard; Daniel J Sexton Journal: JAMA Netw Open Date: 2019-08-02
Authors: Wallis Rudnick; Michelle Science; Daniel J G Thirion; Kahina Abdesselam; Kelly B Choi; Linda Pelude; Kanchana Amaratunga; Jeannette L Comeau; Bruce Dalton; Johan Delport; Rita Dhami; Joanne Embree; Yannick Émond; Gerald Evans; Charles Frenette; Susan Fryters; Greg German; Jennifer M Grant; Jennifer Happe; Kevin Katz; Pamela Kibsey; Justin Kosar; Joanne M Langley; Bonita E Lee; Marie-Astrid Lefebvre; Jerome A Leis; Allison McGeer; Heather L Neville; Andrew Simor; Kathryn Slayter; Kathryn N Suh; Alena Tse-Chang; Karl Weiss; John Conly Journal: Antimicrob Resist Infect Control Date: 2020-02-13 Impact factor: 4.887
Authors: Rebekah W Moehring; Matthew Phelan; Eric Lofgren; Alicia Nelson; Elizabeth Dodds Ashley; Deverick J Anderson; Benjamin A Goldstein Journal: JAMA Netw Open Date: 2021-03-01
Authors: Pranita D Tamma; Melissa A Miller; Prashila Dullabh; Roy Ahn; Kathleen Speck; Yue Gao; Erik Scherpf; Sara E Cosgrove Journal: JAMA Netw Open Date: 2021-02-01
Authors: Yong Chan Kim; Ji Young Park; Bongyoung Kim; Eu Suk Kim; Hyuk Ga; Rangmi Myung; Se Yoon Park; Myung Jin Lee; Song Mi Moon; Sun Hee Park; Kyoung-Ho Song; Hong Bin Kim Journal: Antimicrob Resist Infect Control Date: 2022-02-22 Impact factor: 4.887
Authors: Todd J Vento; John J Veillette; Stephanie S Gelman; Angie Adams; Peter Jones; Katherine Repko; Edward A Stenehjem Journal: Open Forum Infect Dis Date: 2021-06-15 Impact factor: 3.835